Noema Pharma CHF 54m Series A Financing
3 December 2020 – Walder Wyss advised Gilde Healthcare Partners, Polaris Partners, Invus Capital and BioMedInvest as investors on the CHF 54m series A financing of Noema Pharma AG.
Noema Pharma AG is a clinical-stage biotechnology company targeting orphan neurological disorders.
Proceeds from the financing will be used to advance the development of four clinical-stage product candidates.
The Walder Wyss team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital), Robert von Rosen (Partner, Corporate/M&A and Venture Capital), Markus R. Frick (Partner, IP/IT) and Karina Tschon (Associate, Corporate/M&A and Venture Capital).